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SUMMARY: Neuromuscular blocking agents (NMBAs) have been widely used to control patients who need to be immobilized
for some kind of medical intervention, such as an invasive procedure or synchronism with mechanical ventilation. The purpose of
this monograph is to review the pharmacology of the NMBAs, to compare the main differences between the neuromuscular junction
in neonates, infants, toddlers and adults, and moreover to discuss their indications in critically ill pediatric patients. Continuous
improvement of knowledge about NMBAs pharmacology, adverse effects, and the many other remaining unanswered questions
about  neuromuscular junction and neuromuscular blockade in children is essential for the correct use of these drugs. Therefore, the
indication of these agents in pediatrics is determined with extreme judiciousness. Computorized (Medline 1990-2000) and active
search of articles were the mechanisms used in this review.
DESCRIPTORS: Neuromuscular blocking agents. Neuromuscular blocking drugs. Neuromuscular junction.
Neuromuscular block.  Neonate.  Infant.  Child.
Since the introduction of the neu-
romuscular blocking agents (NMBAs)
in 1942, a marked evolution has oc-
curred in these drugs, with progressive
increase in their potency combined
with fewer risks or adverse effects.
Many of these NMBAs have appeared
in the last 10 years, with an increase in
their use in intensive care units1. On the
other hand, the development of new
drugs has made the choice of agents
much more complex, due to differ-
ences in pharmacology, clinical indica-
tions, and side effects of each new
drug2. The NMBAs have been rou-
tinely given to critically ill patients to
facilitate tracheal intubation, for
muscle relaxation during surgery (gen-
erally abdominal and thorax surgery)
and to patients who offer resistance to
mechanical ventilation (despite the use
of intense analgesia and sedation).
In this review, we analyze the phar-
macology of and indications for the old
NMBAs, and we also review the clini-
cal and pharmacologic advances of the
new agents as well as their  complica-
tions.
Physiology of neuromuscular trans-
mission and blockade
Definition: The neuromuscular
blockade can be defined as a reversible
interruption of neuromuscular trans-
mission in the Acetylcholine (AcC)
nicotinic receptors, fin the absence of
any analgesic, sedative or amnesic ac-
tion. In summary, the normal neuro-
muscular transmission is related to the
stimulation of the postsynaptic junc-
tional receptors of AcC that arouse the
depolarization and muscular contrac-
tion3, 4. Nicotinic Receptors:  The neu-
romuscular junction contains some
types of nicotinic receptors:
• Two on the muscle surface;
• one junctional;
• one extrajunctional;
• one presynaptic receptor on the
parasympathetic-nerve ending 5, 6.
The postsynaptic receptors are pro-
teins with five subunits: a , b, c, d e ’ .
Each neuromuscular junction contains
1–10 million nicotinic receptors3, 4, 6.
Physiology of neuromuscular trans-
mission: The neuromuscular transmis-
sion initiates when a nerve impulse ar-
rives on the presynaptic nerve endings,
with liberation of AcC molecules. The
AcC-liberated molecule crosses the
junctional cleft to stimulate the
postsynaptic receptors.
To begin the opening of the chan-
nel receptors, which allow the move-
ment of ions that will finally depolar-
ize the end plate, 2 AcC molecules
must bind simultaneously to two a sub-
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units of a postsynaptic receptor. When
this happens, a brief opening (1 msec.)
of the channel occurs, with a non-se-
lective passage of sodium and calcium
to the muscle, leading to depolarization
of the muscular membrane and muscu-
lar contraction.
Then the AcC molecule is quickly
broken down by the enzyme acetylcho-
linesterase in the junctional cleft, stop-
ping the muscular contraction6.
Physiology of the neuromuscular
blockade: The neuromuscular blockade
can exist by two distinct mechanisms:
• Depolarizing neuromuscular block-
ade;
The neuromuscular blockade by the
classic pathway (depolarizing), be-
gins when a drug bind to the a sub-
unit of the nicotinic receptors like
the molecule of AcC does. In the
beginning, an initial opening of the
ion channel produces a contraction
(fasciculation). After this, the depo-
larization of muscular membrane is
sustained (persistent depolariza-
tion), since the drug is not broken
by acetylcholinesterase, leading to
neuromuscular block.
• Nondepolarizing neuromuscular
blockade;
In the  nondepolarizing neuromus-
cular blockade, the drugs bind in a
competitive way (with AcC) to at
least one a subunit of the nicotinic
receptors. Since there is no biding
of at least two molecules of AcC,
there is no opening of the ion chan-
nels and no muscular depolariza-
tion, with the muscle becoming
flacid6, 7.
Particularities of neuromuscular
blockade in children
There are some characteristic
points in the neuromuscular junction
that differentiate newborns and infants
from other ages.
In the first 2 months of life (in par-
ticular the newborn), the neuromuscu-
lar junction (NMJ) is still developing.
In this maturation phase, the receptors
have an increased metabolic activity8.
The main point that distinguishes
the immature receptors from the devel-
oped ones is a functional difference
that occurs due to a prolonged open-
ing of the ionic channels. This allows
the immature muscles to be more eas-
ily depolarized, and these receptors
have also a greater affinity for depolar-
izing agents and lower affinity for
nondepolarizing agents3, 5, 8, 9.
One of the age-related particulari-
ties is the alteration in the degree of
neuromuscular blockade with the body
composition and the drug distribution.
Since the NMBAs distribute in the ex-
tracellular fluid exclusively, and since
neonates and infants have a larger ex-
tracellular compartment with a higher
volume of distribution, neonates and
infants require high doses of NMBAs
to reach the desired effect. This differ-
ence is decreased in toddlers and
school-aged children that have a vol-
ume of distribution close to Adults (fig-
ure 1)5.
Concerning the alterations concern-
ing the type of muscular fibers (type I,
or slow-twitch, and type II, or fast-
twitch), it is important to note that the
type I fibers are more sensitive to
NMBAs as compared to type II fibers.
Type I fibers have clinical relevance,
since the diaphragm of a neonate has
fewer type I fibers as compared to a
diaphragm of a toddler or a adult. This
makes the diaphragm of a infant more
reactive to NMBAs than his own
peripheric musculature3.
Classification of NMBAs
The NMBAs are classified as fol-
lows:
1) Based on the pharmacologic
mechanism:
a.  Depolarizing drugs;
b.  Nondepolarizing drugs.
2) Based on the biochemical structure:
a.  Benzylisoquinolinium deriva-
tives;
b.  Aminosteroids compounds.
3) Based on the duration of the de-
sired effect:
a.   Short-acting drugs;
b.   Intermediate-acting drugs;
c. Long-acting drugs.
The NMB drugs have many indica-
tions and adverse effects. For this rea-
son, anaesthesiologists and intensivists
are trying to systematize the choice of
the “ideal NMBA”, which has to: have
rapid onset of action and ease of rever-
sion; have low toxic levels; have few
autonomic and cardiovascular effects;
are metabolized and excreted indepen-
dently of the final organic function;
and have low cost.
Depolarizing agents (agonists)
Succinylcholine (Sch): Succinyl-
choline is considered a nondepo-
Figure 1 - Age-related changes in the steady state volume of distribution (Vd) da D-tubocurarine
(curare) parallel maturational changes in the volume of the extracellular fluid space (Vlec). (Fisher et
al.)5.
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larizing NMBA with short action and
is the only nondepolarizing agent avail-
able for clinical use today. Due to its
fast initial action, the main indication
of this drug is for tracheal intubation
(considered the first choice in recent
review)10. Succinylcholine (Sch) is
formed by 2 joined AcC molecules and
rapidly hydrolyzes into succinic acid
and choline by the (pseudo) cholinest-
erase in patients with normal levels of
this enzyme.
Succinylcholine acts by stimulation
of the cholinergic receptors (activation
of the NM junction) that leads to de-
polarization of the musculature. This
causes primarilly a muscular contrac-
tion or fasciculation.
 Succinylcholine has an onset of
action of 30 to 60 seconds and a dura-
tion of  3 to 5 minutes (I.V.). The typi-
cal blockade of Sch (or phase I block-
ade) is obtained in normal doses of 1
to 2 mg/kg/dose. In  cumulative doses
higher than 2 to 4 mg/kg, a alteration
in the type of blockade is obtained
(competitive blockade or phase II
blockade) with a nondepolarizing ac-
tion. This drug has hepatic metabolism,
and 10% of the drug is excreted un-
changed in urine.
Some clinical situations can change
the levels of the plasma cholinesterase,
which can lead to prolonged neuro-
muscular blockade (Table 1).
The most important side effects and
complications of Sch use are:
1) Complications related to depolariza-
tion (muscular fasciculation and pain,
increase in the intracranial pressure,
increase in the intragastric and in-
traocular pressure and displacement of
compound fracture);
2) Prolonged neuromuscular blockade
(plasma cholinesterase deficiency);
3) Cardiovascular effects (dysrhythmias
– generally bradyarrhythmias in chil-
dren, with recommendation to dispose
of atropine for immediate use);
4) Anaphylaxis;
5) Myoglobinemia and myoglobinuria;
6) Hyperkalemia;
7) Malignant hyperthermia (associated
with inhalation anesthetics)11, 12, 13.
Nondepolarizing agents (antagonists)
Short action
Mivacurium: Until the appearance
of rapacuronium, mivacurium was the
only nondepolarizing NMBA classified
as a short-action drug. It is derivative
from benzylisoquinolinium, with 3
times the potency of atracurium (which
is a secondary derivative)14.
It has an onset of action of 1 to 3
minutes and duration less than 30 min-
utes. This drug is metabolized by
plasma cholinesterase (and is altered in
the same clinical situations mentioned
in Sch). It is excreted in the urine. The
normal dose is 0.2 mg/kg/dose.
The potential side effects are:
1) Prolonged neuromuscular blockade
in cases of plasma cholinesterase defi-
ciency or renal failure (metabolites
with renal excretion);
2) Histamine release in rapid infusions
(but with hypotension rarely ob-
served)3, 6, 15.
Rapacuronium:  Rapacuronium is
the newest non-depolarizing NMBA.
This drug is not yet approved for clini-
cal use by the FDA and is under clini-
cal investigation in children. In adults,
rapacuronium has shown an onset of
action as rapid as succinylcholine, with
decreased duration as compared to
mivacurium. Recent studies show a
similar effect in children, with little
cardiovascular effects and histamine
release16.
Intermediate  action
Atracurium: Atracurium is a
bisquaternary intermediate NMBA (an
ammonium benzylisoquinolinium). It
has an onset of action of 2 minutes
with a peak in 5 to 10  minutes. Its du-
ration is about 40 to 60 minutes.
Atracurium is metabolized by sponta-
neous degradation (Hoffman elimina-
tion), a non-enzymatic separation that
occurs at normal temperature and pH.
Atracurium is degraded into acrylate
and laudanosine, which are initiators of
neuromuscular blockade. Laudanosine
has been associated with central ner-
vous system stimulation and convul-
sion.
The normal dose is 0.4 to 0.8 mg/
kg/dose (initial) and 2 to 15 mcg/kg/
minute (continuous infusion).
Hypotension and histamine release
can be associated with rapid infusion
of the drug. Cutaneous erythema is a
common manifestation. Another disad-
vantage of atracurium is the necessity
of higher doses in cases of prolonged
use. Its main advantage is the differ-
ence in its metabolism and the possi-
bility of use in patients with renal or
hepatic failure3, 6, 14, 17.
Cisatracurium: Cisatracurium is a
cis-cis isomer of atracurium. It is a
drug with the same characteristics of
atracurium but stimulates less hista-
mine release and less laudanosine pro-
duction. It has 4 times the potency
combined with low cost as compared
with its isomer. Despite its advantages,
there are a few studies about the use of
this drug in adults and even fewer stud-
ies in children3, 5, 6.
Vecuronium: Vecuronium is a
aminosteroid derivative of
Table 1 – Clinical situations of diminished plasma cholinesterase.
Hepatic disease Organophosphate
Infants until 2 months of life Cyclophosphamide
Burns Neostigmine
Extra-corporeal circulation Malnutrition
Uremia Plasmapheresis
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pancuronium, with an alteration in its
structure (molecular position of 2 me-
thyl N-piperidine). This structural alter-
ation considerably reduces the
vagolytic effects (tachycardia and hy-
pertension) observed with
pancuronium. It has an onset of action
of 1 to 3 minutes and duration of 30
to 40 minutes (dose dependent).
Vecuronium is metabolized 40% to
50% in the liver, and after hepatic hy-
drolysis, 3 of its metabolites have neu-
romuscular blocking activity (one of
them with 70% of the action). These
metabolites are excreted in the urine
(with 15% of accumulation in patients
with renal failure). Its main disadvan-
tage is the prolonged neuromuscular
blockade 3, 6, 18.
The dose is 0.08 to 0.15 mg/kg/
dose (initial) and 0.8 to 1.2 mcg/kg/
minute (continuous infusion).
Rocuronium: Rocuronium is an
aminosteroid derivative of vecuronium
with intermediate-to-short action. It
was recently approved for clinical use
by the FDA (1990). It has the same
characteristics of vecuronium with
higher potency (10% to 15%). This
drug has minimal cardiovascular ef-
fects (just a little increase in cardiac
frequency).19 The onset of action in
children is about 30 to 60 seconds and
the duration is 30 to 40 minutes (equal
in children and adults). It is metabo-
lized by the liver (50% to 60%) with
33% excreted unaltered in the urine.
Due to its fast onset of action in chil-
dren, it is a good option for rapid se-
quence tracheal intubation10.
Long action
Pancuronium: Since its introduc-
tion in 1967, pancuronium has been the
most used NMBA by anesthesiologists
and intensivists. It is a synthetic
aminosteroid that has an onset of ac-
tion of 2 to 3 minutes and half-life of
110 minutes.
About 30% to 40% of this drug is
metabolized by the liver, and it is ex-
creted in the urine (with up to 40% un-
altered drug, which could lead to pro-
longed neuromuscular blockade).
The recomended dose is 0.04 to 0.1
mg/kg.
Pancuronium has many side effects,
most of them related to the cardiovas-
cular system ( e.g., tachycardia, hyper-
tension, increased cardiac output, all
due to vagal block and norepinephrine
release) 3, 20.
Doxacurium: Among the
benzylisoquinolinium derivatives,
doxacurium is the most recently ap-
proved for clinical use. It is the most
potent NMBA (10 times more potent
than d-tubocurarine) with slow action.
It has an onset of action of 6 to 11 min-
utes and a duration of 60 minutes. This
drug binds with plasma proteins (30%)
with minimum metabolism and is
eliminated unaltered in the urine and
bile.
The dose is 0.03 to 0.05 mg/kg/
dose.
Doxacurium is a drug with few side
effects, although it has been associated
with prolonged neuromuscular block-
ade in patients with renal failure 3, 21.
Indications and drug selection
The main indications for the use of
NMBAs are based on the optimization
of immobility of the patient for proce-
dures like:
• Short-term (less than 6 hours):
1)   tracheal intubation;
2)   high-risk invasive procedures.
• Long term (more than 6 hours):
1) synchrony with mechanical
ventilation (dyssynchrony, ex-
cessive hyperventilation or
h y p o v e n t i l a t i o n ,
nonconventional ventilation);
2) reduction of metabolic demand
or work of breathing;
3) treatment of intense agitation
unresponsive to higher doses of
analgesia and sedation;
4) therapeutic hypothermia (de-
creased shivering);
5) protection of surgical repairs.
It’s important to remember that in
all these indications, the use of
NMBAs should be considered in pa-
tients that deep sedation and analgesia
have failed to reach the desired effect.
The choice of the best NMBA be-
comes very difficult and dependent on
the degree and necessity of the muscu-
lar relaxation desired. So the basic cri-
terions should be followed when one is
making the choice for the more ad-
equate NMBA: patient’s age, onset of
action and duration of the drug (de-
pending on the final goal), presence or
absence of hemodynamic instability,
association with other drugs, presence
of organ failure (renal or hepatic); po-
tential risks and side effects (in short
and long term), presence of previous
disease, and the drug’s cost. Pharma-
cologic data about the main NMBAs
are on Table 2.
In September of 1995, the Society
of Critical Care Medicine published an
official statement and best practice pa-
rameters for the use of NMBAs22. The
2 recommendations concerning the use
of NMBAs were classified as level 2 or
reasonably justifiable by available sci-
entific evidence and strongly supported
by expert critical care opinion. The first
recommendation was to use
pancuronium as the preferred NMBA
for most critically ill patients, justified
by the few adverse cardiovascular con-
sequences and the low cost  – an alert
was given for the use in patients with
renal or hepatic failure (to use lower
doses). The second recommendation
was to use vecuronium as the first op-
tion in patients with cardiac disease or
hemodynamic instability, with lower
doses in patients with renal or hepatic
failure.
It is important to note that this con-
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sensus was made for adult patients, and
it must be carefully interpreted for pe-
diatrics since the cardiac effects of
pancuronium are very expressive in
children.
Monitoring the neuromuscular
blockade
Despite its difficulty in daily prac-
tice, the monitoring of the neuromus-
cular blockade should be used
routinelly in intensive care units, due
to the wide variations in the degree of
blockade between the patients. It is
very hard to identify the response ex-
actly in terms of the beginning, the de-
gree, and the duration of the neuromus-
cular blockade. Therefore, monitoring
becomes important for documenting
the presence and degree of blockade
and the return of the normal neuromus-
cular transmission.
Monitoring of the effects of these
drugs is done by the the stimulation of
the ulnar nerve and observation of the
evoked response in the adductor
muscle by a force transductor, by
electroneuromyography, or by visual
inspection.
There are 3 patterns of nerve stimu-
lation: 1) simple stimulus (0.1 to 0.15
Hz); 2) train-of-four (2 hz per 4 sec-
onds or 4 impulses of 0.5 second, re-
peated every 10 seconds), and 3) teta-
nic stimulus (50 to 100 Hz per 5 sec-
onds) 3, 23.
Complications of the use of NMBAs
The great majority of complications
after the use of NMBAs are associated
with long term utilization.
In the last decade, the major de-
scribed complication is the prolonged
muscle weakness after its discontinua-
tion. This complication is well docu-
mented in children, generally with the
use longer than 48 hours. This effect
could last for up to 6 months24. There
are 2 patterns of neuromuscular dys-
function: the persistent block of the
NM junction (PBNMJ) and the acute
myopathy 25.
PBNMJ is the complication that
has more clinical significance, prob-
ably due to the accumulation of drugs
or its active metabolites (mainly in pa-
tients with renal or hepatic failure).
Another pattern of PBNMJ is the one
that begins when an aminosteroid
NMBA and corticosteroids are used to-
gether 26, 27. This association of drugs
is important since one of the major in-
dications of NMBAs in pediatrics is the
child with status asthmaticus with
dyssynchrony with mechanical ventila-
tion (and who uses short or long-term
corticosteroids). This kind of PBNMJ
was also recently  described  with the
association of benzylisoquinolinium
derivatives and corticosteroids 28.
The acute myopathy also leads to
prolonged paralysis, but is not caused
by delayed recuperation of the NM
junction 25.
Muscular atrophy, joint contrac-
tures, thrombotic or embolic events,
ulcers of the skin, atelectasis, pneumo-
nia, and corneal drying are other pos-
sible complications. Special attention
should be given to the neurologic
evaluation of the patient receiving
NMBAs (attention to status epilepticus
and monitoring with electro-encepha-
logram) and the assessment of pain and
anxiety (sweaty brow, tearing, hyper-
tension, and tachycardia could be signs
of pain or anxiety)3,5, 6,9.
With the knowledge of all these
complications, the NMBAs shoud be
used only when profound analgesia
and sedation have failed to reach the
desired effect and when used, bolus
doses are preferred and continuous and
prolonged infusions should be avoided.
Final considerations
The NMBA continue to be fre-
quently used drugs in pediatric inten-
sive care units. Continuous updating
concerning the pharmacology of the
NMBAs (mainly the new ones) is nec-
essary for the correct evaluation of the
indications for each drug and to avoid
adverse effects. Many questions about
the physiology of the neuromuscular
junction and about the NMBAs and
their complications in children remain
unanswered, which indicates a very ju-
dicious use of these drugs in children.
Table 2 – Pharmacology of non-depolarizing NMBAs.
Pancuronium Atracurium Vecuronium Doxacurium Mivacurônio
Year introd 1972 1983 1984 1991 1988
Initial dose (mg/kg) 0,1 0,4-0,5 0,1 0,05 0,2
Duration (min) 90-100 25-3 35-45 120-150 <30
Continuous(mcg/kg/m) 1-2 4-12 1-2 ? 1-15
Reversion (min) 120-180 40-60 46-60 120-180 15-20
Histamine liber. no minim /dose dep  variable ? minim.
Vagal  block important no no no no
Gangl. block no minim. no no no
Prolong. NMB yes rare yes yes yes
Cost low  interm./high  interm. high high
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RESUMO RHCFAP/3012
ALMEIDA J F L de e col. – Bloquea-
dores neuromusculares em crian-
ças. Rev. Hosp. Clín. Fac. Med. S.
Paulo 55(3):105-110, 2000.
Os bloqueadores neuromusculares
têm sido amplamente utilizados para
controlar pacientes que necessitem
imobilidade para algum tipo de inter-
venção médica, desde a realização de
procedimentos invasivos até a obtenção
de sincronismo com a ventilação me-
cânica. O objetivo básico desta mono-
grafia é revisar a farmacologia dos
principais bloqueadores neuromuscu-
lares, analisar as diferenças existentes
na junção neuromuscular de neonatos,
lactentes, pré-escolares e adultos, além
de discutir suas indicações em pacien-
tes criticamente enfermos internados
em unidade de terapia intensiva pe-
diátrica. Revisão computadorizada da
literatura (Medline 1990-2000) associ-
ado a busca ativa de artigos compuse-
ram o mecanismo de busca dos dados
desta revisão.
DESCRITORES: Bloqueadores
neuromusculares.  Junção neuro-
muscular. Bloqueio neuromuscular.
Neonatos. Lactentes. Crianças.
REFERENCES
1. MURRAY MJ, STRICKLAND RA & WEILER C - The use of
neuromuscular blocking drugs in the intensive care unit: A US
perspective. Intensive Care Med 1993; 19:S40-S44.
2. MARTIN LD, BRATTON SL  &  O’ROURKE PP - Clinical uses and
controversies of neuromuscular blocking agents in infants and
children. Crit Care Med 1999: 27(7): 1358-1368.
3. MARTIN JAJ, WHITE DA, GRONERT GA et al. - Up and down
regulation of skeletal muscle acetylcholine receptors.
Anesthesiology 1992; 76: 822-843.
4) RAMA SASTRY BV - Nicotine receptor. Anaesth Pharmacol Rev
1993; 11:219-236.
5. FISCHER DM - NMBA in paediatric anaesthesia. Br J Anaesth 1999;
83(1):58-64.
6. HUNTER JM - New neuromuscular blocking drugs. N Engl J Med
1995; 332(25): 1691-1699.
7. RAMSEY FM - Basic Pharmacology of neuromuscular blocking
agents. Anesth Clin North Am 1993; 11:219-236.
8. GOUDSOUZIAN NG - Maturation of the neuromuscular transmission
in infant. Br J Anaesth 1980; 52:205-213.
9. GRONERT BJ & BRANDOM BW - Neuromuscular Blocking Drugs
in Infants and Children. Ped Anesth 1994; 41:73-91.
10. McALLISTER JD & GNAUCK KA - Rapid Sequence Intubation of
the Pediatric Patient – Fundamentals of  Practice. Pediatr Clin
North Am 1999; 46(6): 1249-1284.
11. OREBAUGH SL - Succinylcholine: Adverse Effects and Alternatives
in Emergency Medicine. Am J  Emerg Med 1999; 17(7): 715-
721.
12. BASTA SJ - Modulation of histamine release by neuromuscular
blocking drugs. Curr Opin Anaesthesiol  1992; 5:572-576.
13. PRIELIPP RC & COURSAN DB - Applied Pharmacology of Common
Neuromuscular Blocking Agents in Critical Care. New Horizons
1994; 2:34-47.
14. BELMONT MR et al. - Pharmacodinamics and pharmacokinetics of
benzylisoquinolinium (curare-like) neuromuscular blocking drugs.
Anesth Clin North Am 1993; 11:251-283.
15. MIRAKUR RK - Neuwer neuromuscular blocking drugs: a overview
of their clinical pharmacology and therapeutic use. Drugs 1992;
44:182-199.
16. KAPLAN RF, FLETCHER JE, HANNALLAH RS et al. - The Potency
(ED50) and Cardiovascular Effects of Rapacuronium (Org 9487)
During Narcotic-Nitrous Oxide Propofol Anesthesia in Neonates,
infants and Chlidren. Anesth Analg 1999;89:1172-6.
17. BASTA SJ, SAVARES JJ, ALI HH et al. - Histamine release potencies
of atracurium and dimethyl-tubocarine. Br J Anaesth 1983;55:105S-
111S.
18. MEISTELMAN C, AGOSTON S, KERSTEN UW et al. -
Pharmacokinetics and pharmacodynamics of vecuronium and
pancuronium in anesthetized children. Anesth Analg 1986;65:1319-
1323.
19. WRIGHT PMC et al. - Onset and duration of rocuronium and
succinylcholine at the adductor pollicis and laryngeal adductor
muscles in anesthetized humans. Anesthesiology 1994;81:1110-
1115.
20. LEMOS JM, CARR RR, SHALANSKY KF et al - Paralysismin the
critically ill: Intermittent bolus pancuronium compared with
continuous infusion. Crit Care Med 1999;27(12):2648-2655.
21. BASTA SJ, SAVARES JJ, ALI HH et al - Clinical pharmacology of
doxacurium chlotide: a new long-acting non-depolarizing muscle-
relaxant. Anesthesiology 1988;69:478-486.
22. SCCM - Practice Parameters for Sustained Neuromuscular Blockade
in the Adult Critically Ill Patient: Official Statement of the Society
of Critical Care Medicine. 1995.
23. DAVIDSON JE - Neuromuscular blockade: Indications, Peripheral
Nerve Stimulation and other concurrent interventions. New
Horizons 1994;2:75-84.
24. WOKKE JHJ, JENNEKENS FGI et al. - Histological investigations of
muscle atrophy and end plates in two critically ill patients with
generalized weakness. J Neurol Sci 1988;88:95-106.
25. WACLAWIK AC, SUFIT RL, et al. -  Acute myopathy with seletive
degradation of myosin filaments following status asthmaticus. J
Neurol Sci 1990;98(Suppl:470).
26. HIRANO M, OTT B,RAPS E, et al. - Acute quadriplegic myopathy: a
complication of treatment with steroids, nondepolaring  blocking
agents or both. Neurology 1992;42:2082-2087.
27. LARSSON L et al. - Acute quadriplegia and loss of muscle myosin in
patients treated with  ND-NMBA and corticosteroids: Mechanisms
at the cellular and molecular levels. Crit Care Med 2000; 28(1):
34-45.
28. MEYER KC et al. - Prolonged weakness after infusion of atracurium in
two intensive care unit patients. Anesth Analg 1994; 78:772-774.
29. SCHVARTSMAN S & SCHVARTSMAN C -  Pronto Socorro de
Pediatria. 2o ed. São Paulo, Sarvier 1999. c. 6.
Received for publication on the 03/05/00
